TheraCryf PLC

8EV

Company Profile

  • Business description

    TheraCryf PLC is a biotechnology company developing new medicines for addiction and other neuropsychiatric disorders, areas of unmet medical need within central nervous system (CNS) disorders. The Group's main programme is a novel, benchmark orexin-1 receptor antagonist being developed as a potential treatment for addiction, including binge eating, alcohol, and other substance use disorders. It also has a dopamine transporter (DAT) modulator programme addressing fatigue of brain origin, including fatigue associated with multiple sclerosis, chemotherapy, and narcolepsy. The Group also has an oncology programme in glioblastoma with SFX-01. It operates a capital-light, virtual development model advancing programmes to early clinical or proof-of-concept stage before partnering.

  • Contact

    Congleton Road
    Alderley Park
    Nether AlderleyCheshireSK10 4TG
    GBR

    T: +44 1625315090

    E: [email protected]

    https://www.evgen.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 March 2027

    Employees

    9

Stocks News & Analysis

stocks

Why don’t good returns guarantee a 5-star rating?

Amy Arnott explains how Morningstar’s stock ratings work.
stocks

Despite post earnings rally ASX share still cheap

Lifting our 2028 earnings estimate by 20%.
stocks

Overvalued ASX share has overly ambitious profit target

We think the new profit target is aggressive and unlikely to be met.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,997.30168.10-1.83%
CAC 408,216.78135.22-1.62%
DAX 4026,045.37553.27-2.08%
Dow JONES (US)50,759.42848.75-1.64%
FTSE 10010,689.87191.68-1.76%
HKSE23,508.17245.67-1.03%
NASDAQ24,328.38181.38-0.74%
Nikkei 22558,860.43801.59-1.34%
NZX 50 Index14,348.6441.680.29%
S&P 5007,340.5376.06-1.03%
S&P/ASX 2008,883.20161.50-1.79%
SSE Composite Index3,584.5817.99-0.50%

Market Movers